anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence of hamstring muscle strain varies among muscles, suggesting that the mechanical stresses associated with elongation may differ among muscles. However, the passive mechanical properties of whole human muscles have rarely been directly measured and clarified. This study aimed to clarify the stress-strain relationship of the hamstring muscles using a soft-embalmed Thiel cadaver. The long heads of the biceps femoris (BFlh), semimembranosus (SM), and semitendinosus (ST) muscles were dissected from eight cadavers. The proximal and distal hamstring tendons were affixed to the mechanical testing machine. Slack length was defined as the muscle length at the initial loading point detected upon the application of a tensile load. Muscle length was measured using a tape measure, and the anatomical cross-sectional area (ACSA) of the muscle was measured at the proximal and distal sites using B-mode ultrasonography. In the loading protocol, the muscle was elongated from its slack length to a maximum of 8% strain at an average rate of 0.83 L0/s, and the amount of displacement and tensile load were measured for each muscle. Further, the strain (%, displacement/slack muscle length) and stress (kPa, tensile load/ACSA) were calculated to evaluate the mechanical properties. Two-way repeated-measures analysis of variance (ANOVA) was used to compare stress changes with increasing muscle strain. A significant interaction between the muscle and strain factors was observed with respect to stress. Post-hoc tests revealed higher stresses in the BFlh and SM than in ST after 3% strain (P < 0.01). However, no significant differences were observed between the BFlh and SM groups. At 8% strain, the BFlh, SM, and ST exhibited stresses of 63.7 ± 12.1, 53.7 ± 23.2, and 21.0 ± 11.9 kPa, respectively. The results indicate that the stress changes associated with muscle strain differed among muscles. In particular, the stress applied to the three muscles at the same strain was found to be higher in the BFlh and SM. Thus, these findings suggest that increased mechanical stress during elongation may contribute to the frequent occurrence of muscle strain in BFlh and SM.
Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
This parallel, 2-arm, blinded, randomized controlled superiority trial examined whether, when added to usual care, active-electroencephalography neurofeedback (EEG NFB) was safe and more effective than sham control-EEG NFB for chronic pain. In total, 116 participants with chronic pain were randomly assigned (1:1) to usual care plus ≥32 sessions of active-EEG NFB upregulating relative alpha power over C4 or usual care plus ≥32 sessions of sham control-EEG NFB. Per-protocol analyses revealed no significant between-group differences in the primary outcome, Brief Pain Inventory average pain (mean difference [95% confidence interval]: -.04 [-.39 to .31], P = .90), or any secondary outcomes. However, 44% of participants in the active-EEG NFB group and 45% in the control-EEG NFB group reported at least a moderate (≥30%), clinically important improvement in Brief Pain Inventory average pain. The number of treatment-emergent adverse events were similar in both groups (P = .83), and none were serious. Post hoc analyses revealed similar upregulated relative alpha power in both groups during training, with concordant positive rewards delivered to the active-EEG group 100% of the time and the control-EEG group ∼25% of the time, suggesting a partially active sham intervention. When added to usual care, the active-EEG NFB intervention used in this study was not superior to the sham control-EEG NFB intervention. However, a large proportion of participants in both groups reported a clinically important reduction in pain intensity. A partially active sham intervention may have obscured between-group differences. The intervention was free of important side effects, with no safety concerns identified. PERSPECTIVE: This study is the first attempt at an appropriately blinded, randomized, sham-controlled trial of alpha EEG NFB for the treatment of chronic pain. The findings may interest people living with chronic pain, clinicians involved in chronic pain management, and may inform the design of future EEG NFB trials. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000667819.
All study participants will receive 4 initial CR sessions. Afterwards, they will be randomized, and this group will receive an additional tune-up (maintenance) session every 6 weeks for one year. There will be a CR session at weeks 6, 12, 18, 24, 30, 36, 42, and 48.
The invention discloses a method for treating gastrointestinal diseases, relates to a polybasic biological bacteria liquid prepared through bacteria fermentation by using hericium erinaceus, and aims at providing a biological bacteria liquid with treatment and maintenance effects on multiple gastrointestinal diseases and a preparation method of the biological bacteria liquid. The biological bacteria liquid is an oral liquid and can be used as a drug or a functional drink. The preparation method of the biological bacteria liquid for treating the gastrointestinal diseases comprises the steps of preparation of a traditional Chinese medicinal culture medium, inoculation and fermentation. According to the biological bacteria liquid, the principle of double functions of the hericium erinaceus and a gastrointestinal probiotic liquid on the gastrointestinal diseases is cleverly utilized, so that the traditional medicine is perfectly combined with a modern biotechnology to serve human health. The hericium erinaceus is a traditional medicinal and edible common material and the biological bacteria liquid obtained through inoculating the hericium erinaceus into probiotics as a raw material of the culture medium has bilateral safety. The biological bacteria liquid disclosed by the invention is excellent in taste, can be blended with wine to form low wine. The biological bacteria liquid belongs to the field of medicines and functional drinks.
The invention discloses a Chinese medicinal herb preparation for poultry. The effective constituents of a Chinese medicinal herb product disclosed by the invention are made up of echinacea purpurea, honeysuckle, hypericum perforatum, glycyrrhiza, folium isatidis, platycodon grandiflorum, lophatherum gracile, mint and hypericin. The Chinese medicinal herb preparation disclosed by the invention can relieve the exterior syndrome with drugs pungent in flavor and cool in property and clear away heat and toxic materials; and the main therapeutical effects include strengthening vital Qi and eliminating pathogens, balancing Yin and Yang, and improving non-specific immunity of organisms. The Chinese medicinal herb preparation for poultry has significant therapeutical effect for depressed spirit of poultry, feed intake decrease, egg laying reduction, eyelid swelling of poultry caused by unknown viruses, respiratory inflammation, yellow-green dung, weight increment decline, soft-shelled eggs, and death rate increment, etc.; furthermore, the Chinese medicinal herb preparation for poultry can be utilized to prevent the diseases of untypical Newcastle disease and avian influenza etc. and treat the relevant mixed infection, secondary infection, untypical diseases and chronic cases; and finally, the Chinese medicinal herb preparation for poultry well promotes the recovery of production performance after the poultry is healed.
PURPOSE: A novel compound isolated from Aspergillus sp. KMD901 is provided to be used as a anticancer agent. CONSTITUTION: An Aspergillus sp. strain(deposit number KCCM 11047P) is derived from marine deposit soil. A composition for preventing or treating cancer contains Aspergillus sp. strain, culture material of the strain, dried material or concentrate of the culture material, organic solvent extract which is obtained from the culture using ethyl acetate, alcohol of C1-C4, methylene chloride, ether, or chloroform, or fraction. A composition for preventing or treating cancer contains acetylaranotin of chemical formula 1, acetylapoaranotin of chemical formula 2, dehydro-deoxyapoaranotin of chemical formula 3 or pharmaceutically acceptable salt thereof as an active ingredient.
The day before their scheduled appointment, participants will be asked if they have completed a series of easy health behaviors (e.g., whether they walked 500 feet yesterday, at least two serving of fruits and vegetables in the last week, and slept at least 6 hours the previous night). They will then be encouraged to get a flu shot at their appointment.
BACKGROUND: Open Bankart repair plus inferior capsular shift and isolated arthroscopic Bankart repair have never been prospectively compared under the concept of glenoid track in collision athletes with recurrent anterior shoulder instability. The aim of this study was to compare the functional outcomes, range of motion, and recurrence rate between these 2 surgical techniques. We hypothesized that open Bankart repair plus inferior capsular shift would provide similar functional outcomes to isolated arthroscopic Bankart repair but with a lower recurrence rate.
METHODS: A prospective cohort study was conducted with 86 collision athletes divided into 2 groups of 43 patients each. All patients had a subcritical glenoid bone loss ≤13.5% and an on-track Hill Sachs lesion. The average follow-up was 66 (60-93) months for the open group and 68 (60-97) months for the arthroscopic group. The primary functional outcomes of each group were evaluated at baseline, 6 months, 1 year and for a minimum of 5 years after surgery. The functional outcomes were also compared between the 2 groups. The assessment tools included the Western Ontario Shoulder Instability Index (WOSI) score and American Shoulder and Elbow Surgeons scale (ASES) score. In addition, recurrent instability and range of motion were also evaluated.
RESULTS: In each group, there were significant differences in Western Ontario Shoulder Instability Index score and American Shoulder and Elbow Surgeons scale score between the pre and postoperative periods. There were no differences between the groups at the end of follow-up (P = .47 and .22). Three dislocations (6.9%) in the open group and 10 dislocations (23.2%) in the arthroscopic group were reported showing significant differences (P = .012). In addition, there were no differences in range of motion between pre and postoperative periods for each group as well as between them.
CONCLUSION: We found no differences in functional outcomes and range of motion between the 2 groups. The recurrence rate was significantly higher in the arthroscopic group. We recommend performing open Bankart repair plus inferior capsular shift as a treatment alternative in collision athletes with recurrent anterior shoulder instability.
Sodium valproate (VPA), a histone deacetylase (HDAC) inhibitor, could be a promising candidate to treat acute myocardial infarction (AMI). In this study, AMI was induced in New Zealand White rabbits by occluding the left circumflex coronary artery for 1 h, followed by reperfusion. The animals were distributed into three experimental groups: the sham-operated group (SHAM), the AMI group and the AMI + VPA group (AMI treated with VPA 500 mg/kg/day). After 5 weeks, abdominal aorta was removed and used for isometric recording of tension in organ baths or protein expression by Western blot, and plasma for the determination of nitrate/nitrite (NOx) levels by colorimetric assay. Our results indicated that AMI induced a reduction of the endothelium-dependent response to acetylcholine without modifying the endothelium-independent response to sodium nitroprusside, leading to endothelial dysfunction. VPA treatment reversed AMI-induced endothelial dysfunction and even increased NO sensitivity in vascular smooth muscle. This response was consistent with an antioxidant effect of VPA, as it was able to reverse the superoxide dismutase 1 (SOD 1) down-regulation induced by AMI. Our experiments also ruled out that the VPA mechanism was related to eNOS, iNOS, sGC and arginase expression or changes in NOx plasma levels. Therefore, we conclude that VPA improves vasodilation by increasing NO bioavailability, likely due to its antioxidant effect. Since endothelial dysfunction was closely related to AMI, VPA treatment could increase aortic blood flow, making it a potential agent in reperfusion therapy that can prevent the vascular damage.
This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
FIELD: medicine, therapeutic stomatology. SUBSTANCE: treatment method involves using proteolytic enzyme, application of ointment of the complex composition on fissure and all red border of lips, carrying out lidocaine blockade with preliminary premedication with apo-diazepam in the dose 5 mg by sublingual route, using ointment "Lorinden C", carrying out the section by helium-neon laser on damaged lip sites, prescribing anti-histaminic preparations, antiallergic diet and correction of psychoemotional state. Treatment is carried out on the background of every day application of oral gels for lips protection and intaking polyvitamins. Homeopathic ointment "Traumel" is prescribed for children instead ointment "Lorinden C". Method exhibits high effectiveness and after carried out treatment relapses of diseases are absent and neurodystrophic and inflammatory processes around lips and perioral skin are eliminated. EFFECT: improved and enhanced effectiveness of treatment. 1 tbl, 3 ex
Vulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery. This condition significantly impacts the quality of life for cancer survivors, leading to persistent discomfort, heightened infection risk, and negative effects on sexual function and self-esteem. Despite being a relatively common complication, vulvovaginal atrophy is not always discussed before the start of treatment. Treatments typically mirror those used for natural menopause; however, efficacy and safety data specific to this population are limited due to the exclusion of these patients from clinical trials. A major safety concern is the risk of hormone-sensitive cancer recurrence associated with estrogen therapy, which drives a preference for non-hormonal alternatives. Newer treatments, such as laser therapy, radiofrequency, and vaginal injections, show promise with minimal side effects and hormone-independent mechanisms, though efficacy data varies, highlighting the need for further research. This narrative review explores the epidemiology, risk factors, diagnosis, and management of vulvovaginal atrophy after the treatment for oncogynecologic disorders.
Tuinal is an important physical therapy method in traditional Chinese medicine, which can be traced back to the Shang Dynasty around 2700 BC. With the continuous development of social economy and cultural exchange, Tuinal technology based on traditional Chinese medicine ethics and guided by modern scientific theories gradually emerged. The technical treatment methods are mainly relaxation techniques, supplemented by movement techniques. Following the principle of combining movement and stillness, emphasizing both muscles and bones, and progressing step by step, massage has significant therapeutic effects on skeletal muscle diseases. In clinical practice, massage therapists use various techniques to apply to specific parts or acupoints of the human body, keeping the nerves and muscle tissues in a good state, improving the unblocking of meridians, relaxing soft tissues, restoring flexibility, and relieving symptoms such as muscle spasms and pain.
PURPOSE: A composition containing panduratin derivatives, salt thereof, or Boesenbergia pandurata extract is provided to recover fatigue and enhance muscle amount without side effect. CONSTITUTION: A composition for improving exercise capability contains panduratin derivatives or salt thereof as an active ingredient. The panduratin derivatives are panduratin A of chemical formula 1, 4-hydroxypanduratin A of chemical formula 2, or isopanduratin A of chemical formula 3. The panduratin derivatives are isolated from Boesenbergia pandurata. A composition for improving exercise capability contains the Boesenbergia pandurata extract as an active ingredient. A composition for anti-fatigue contains the panduratin derivatives or salt thereof as an active ingredient.
PURPOSE: A composition containing Phllostachys nigra var. henosis extact for preventing or treating transplant rejection or autoimmune diseases is provided to suppress IFN-gamma and Th1 and Th2 response. CONSTITUTION: A composition for preventing or treating transplant rejection or autoimmune disease contains Phllostachys nigra var. henosis extract as an active ingredient. The Phllostachys nigra var. henosis extract is isolated using water, alcohol of 1-4 carbon atoms, or ethyl acetate. The ethyl acetate extract is an ethyl acetate soluble fraction prepared by removing methylene chloride soluble fraction from water extract of Phllostachys nigra var. henosis and isolating with ethyl acetate.
The invention provides a making method for pomegranate rind electuary and relates to the technical field of processing of pomegranate rinds. The making method comprises the steps: soaking the pomegranate rinds in water for 6-8 hours, quickly freezing and slicing the soaked pomegranate rinds, wherein the slicing thickness is 0.7 mm, soaking the slices by warm water, taking out the slices, soaking the slices in honey water, naturally fermenting the pomegranate rind slices wetted with the honey water for 16-20 hours, and drying the pomegranate bark slices; smashing the dried pomegranate bark slices to 30 meshes, wrapping the pomegranate bark slices by edible glycerinum, then stewing the pomegranate bark slices by steam for 30 minutes, and drying and smashing the pomegranate bark slices to 110-mesh pomegranate powder granules; and roasting the pomegranate powder granules to prepare the pomegranate bark electuary. The pomegranate bark electuary prepared by the making method provided by the invention can be directly mixed with boiled water to eat. The pomegranate barks are debitterized many times, so that the purpose of removing bitterness of the pomegranate barks is finally realized. Moreover, the taste of the pomegranate barks is improved by using honey and edible glycerinum, so that the prepared pomegranate powder electuary is slightly sweet and tasty and free of bitterness. Moreover, effective officinal components in the pomegranate barks are further retained, so that the food plays the roles of expelling parasites, inhibiting bacteria and preventing cold.
If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
AT will consist of individualized walking delivered up to 7 times per week to achieve a cumulative total duration of: Arm 1: 90 min/wk. AT therapy within each arm will follow a non-linear (i.e., AT dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule delivered during chemotherapy. Supervised AT will be monitored using TeleEx.
Risk Summary

There are no available data on the use of PARSABIV in pregnant women. In animal reproduction studies, effects were seen at doses associated with maternal toxicity that included hypocalcemia. In a pre- and post-natal study in rats administered etelcalcetide during organogenesis through delivery and weaning, there was a slight increase in perinatal pup mortality, delay in parturition, and transient effects on pup growth at exposures 1.8 times the human exposure for the clinical dose of 15 mg three times per week. There was no effect on sexual maturation, neurobehavioral, or reproductive function in the rat offspring. In embryo-fetal studies, when rats and rabbits were administered etelcalcetide during organogenesis, reduced fetal growth was observed at exposures 2.7 and 7 times exposures for the clinical dose, respectively.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

There were no effects on embryo-fetal development in Sprague-Dawley rats when etelcalcetide was dosed at 0.75, 1.5, and 3 mg/kg/day by the intravenous route during organogenesis (pre-mating to gestation day 17) at exposures up to 1.8 times human exposures at the clinical dose of 15 mg three times per week based on AUC. No effects on embryo-fetal development were observed in New Zealand White rabbits at doses of etelcalcetide of 0.375, 0.75, and 1.5 mg/kg by the intravenous route (gestation day 7 to 19), representing up to 4.3 times human exposures based on AUC. In separate studies at higher doses of 4.5 mg/kg in rats (gestation days 6 to 17) and 2.25 mg/kg in rabbits (gestation days 7 to 20), representing 2.7- and 7-fold clinical exposures, respectively, there was reduced fetal growth associated with maternal toxicities of hypocalcemia, tremoring, and reductions in body weight and food consumption.

In a pre- and post-natal development study in Sprague-Dawley rats administered etelcalcetide at 0.75, 1.5, and 3 mg/kg/day by the intravenous route (gestation day 7 to lactation day 20), there was a slight increase in perinatal pup mortality, delay in parturition, and transient reductions in post-natal growth at 3 mg/kg/day (representing 1.8-fold human exposures at the clinical dose of 15 mg three times per week based on AUC), associated with maternal toxicities of hypocalcemia, tremoring, and reductions in body weight and food consumption. There were no effects on sexual maturation, neurobehavioral, or reproductive function at up to 3 mg/kg/day, representing exposures up to 1.8-fold human exposure based on AUC.